Comparison of Prognostic Indices in Japanese Patients with Diffuse Large B-cell Lymphoma in the Yonago Area by Hosoda, Yuzuru et al.
58
Yonago Acta Medica 2018;61:058–065   Original Article
Corresponding author: Yuzuru Hosoda, PhD 
yhosoda@med.tottori-u.ac.jp
Received 2017 November 30
Accepted 2018 January 19 
Abbreviations: AIC, Akaike’s information criteria; AUC, area under 
the receiver operator characteristics curve; CI, confidence interval; 
CPE, concordance probability estimate; DLBCL, diffuse large 
B-cell lymphoma; IPI, international prognostic index; NCCN, Na-
tional Comprehensive Cancer Network; OS, overall survival; PFS, 
progression-free survival 
Comparison of Prognostic Indices in Japanese Patients with Diffuse Large B-cell 
Lymphoma in the Yonago Area
Yuzuru Hosoda,*† Norihiko Hino† and Toru Motokura*
*Division of Clinical Laboratory Medicine, Department of Pathophysiological and Therapeutic Science, School of Medicine, Tottori 
University Faculty of Medicine, Yonago 683-8503, Japan and †Department of Hematology, Tottori University Hospital, Yonago 683-
8504, Japan
ABSTRACT
Background    Several prognostic indices for diffuse 
large B-cell lymphoma (DLBCL) have been developed. 
Which index is appropriate for Japanese patients with 
DLBCL treated in real-world practice is unknown.
Methods    The prognostic performances of the original 
international prognostic index (IPI), age-adjusted IPI, 
National Comprehensive Cancer Network-IPI, elderly 
IPI and revised IPI were compared using patients with 
DLBCL treated in a single institute in the Yonago area 
in Japan.
Results    From 2005 through 2015, 182 patients with 
de novo DLBCL were treated with chemotherapy in 
Tottori University Hospital; 154 (85%) patients received 
R-CHOP (rituximab, cyclophosphamide, doxorubicin, 
vincristine and prednisolone) although full dose was ad-
ministered in 63 (35%) patients. The median age of the 
patients was 71 years (range 18 to 91). Three-year overall 
survival rate was 71.8% (95% CI, 64.1% to 78.2%). All 
indices significantly discriminate risk groups for overall 
survival of the patients (P < 0.001). Although no statis-
tical difference of performance was found among these 
indices, the best scores of model fit/discrimination mea-
sures were beaten out by age-adjusted IPI, the simplest 
and three-factor model.
Conclusion    Age-adjusted IPI is still usable in re-
al-world practice while a better predictive model is de-
sired for Japanese patients with DLBCL.
Key words    lymphoma, large B-cell, diffuse; progno-
sis; rituximab; aged; Japan
The International Prognostic Index (IPI) is a prognostic 
model developed in 1993, using 3273 patients of all ages 
with aggressive non-Hodgkin lymphoma treated with 
cyclophosphamide, doxorubicin, vincristine and predni-
sone (CHOP)-like chemotherapy.1 The five pretreatment 
risk factors, i.e., age (≤ 60 vs. > 60), tumor stage (stage 
I or II vs. stage III or IV), number of extranodal sites 
of disease (≤ 1 vs. > 1), performance status (0 or 1 vs. 
≥ 2) and serum lactate dehydrogenase level (≤ 1 vs. > 1 
times normal), were identified and four risk categories 
were made. Patients with the number of risk factors 4 or 
5 were assigned to a high-risk group, 5-year survival of 
which was 26%. In addition, using 1274 patients aged 60 
years or younger, age-adjusted IPI was also made based 
on tumor stage, lactate dehydrogenase and performance 
status because the age limit for patients treated by most 
intensive experimental regimens for non-Hodgkin’s 
lymphoma was 60 years.1 In the advent of rituximab, the 
prognosis of B-cell lymphoma improved dramatically 
and the IPI is no longer potent especially in discriminat-
ing the subgroup of patients with poor prognosis. Then, 
new prognostic models were developed and evaluated 
for predicting the prognosis of patients with diffuse large 
B-cell lymphoma (DLBCL), a major subtype of aggres-
sive lymphoma; these are revised IPI,2 elderly IPI3 and 
National Comprehensive Cancer Network (NCCN)-IPI.4 
The revised-IPI regrouped the original IPI factors into 
3 risk categories.2 The elderly IPI used the cut-off point 
of age at 70 years instead of 60 years in the IPI.3 The 
NCCN-IPI subdivided age to 4 levels (≤ 40 vs. > 40 to ≤ 
60 vs. > 60 to ≤ 75 vs. > 75) and lactate dehydrogenase 
into 3 levels (≤ 1 vs. > 1 to ≤ 3 vs. > 3 times normal).4 In 
addition, the involvement of bone marrow, liver/gastro-
intestinal tract, lung and/or central nervous system was 
considered as a factor instead of the number of extranod-
al sites of disease. These indices were elaborated based 
on clinical data of non-Japanese patients and which 
index is appropriate for Japanese patients with DLBCL 
treated in real-world practice is unknown.
 Tottori University Hospital is a tertiary hospital 
located in Yonago City with a population of 148,000 
inhabitants, surrounded by a rural area in Tottori pre-
fecture, where the population is rapidly ageing and 
the proportion of people aged older than 65 years was 
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27.6% according to the national census in 2015. In this 
area, our hospital is one of the two hospitals in which 
patients with lymphoma are treated with curative intent. 
We reviewed the clinical records of Japanese patients 
with DLBCL treated in Tottori University Hospital from 
2005 through 2015 and compared the predictive power 
of these indices.
MATERIALS AND METHODS
Patients and Methods
This study is a retrospective analysis of an unselected 
patients with newly diagnosed de novo DLBCL who 
were consecutively treated in Tottori University Hospital 
from April 2005 through December 2015. Patients were 
included for analysis in this study if they received any 
anti-cancer drug and were at least 16 years old at the 
time of treatment and the clinical records were reviewed. 
R-CHOP immunochemotherapy was the standard reg-
imen and 80% dose of doxorubicin, vincristine and 
cyclophosphamide was delivered in patients older than 
80 years of age and subsequent dose was adjusted at the 
doctor’s discretion. For frail patients, doxorubicin and/
or other drugs were removed from the regimen and even 
ad libitum administration of a couple of drugs was done. 
In case of central nervous system involvement, R-MPV 
(rituximab, methotrexate, procarbazine and vincristine) 
regimen was preferred.5 The study was approved by the 
Ethics Committee at Tottori University Faculty of Medi-
cine (approval number 2489).
Statistical methods
Overall survival (OS) was calculated from the date of 
initial chemotherapy until death from any cause. Progres-
sion-free survival (PFS) was calculated from the date of 
initial chemotherapy to documented disease progression, 
relapse and death from any cause; observations were cen-
sored on the date the patient was last known to be alive. 
The follow-up cut-off point was December 31, 2016. OS 
and PFS were assessed using the Kaplan-Meier method 
and risk groups were compared using the log-rank test. 
Performances of prognostic indices were compared by a 
measure of global fit (Akaike’s information criteria, AIC) 
and by a measure of discrimination (concordance probabil-
ity estimate, CPE).6, 7 Low values of AIC indicate better fit 
and high values of CPE indicate better discrimination. The 
area under the receiver operator characteristic curve (AUC) 
over time was also used to compare between these indices 
and an integrated AUC was calculated as a time-depen-
dent concordance measure.8 Univariate and multivariate 
analysis of prognostic factors was performed using the Cox 
proportional hazard regression model. Data were analyzed 
using EZR (ver. 1.36)9 and R (ver. 3.4.0) software.
RESULTS
Patients and treatments
From April 2005 through December 2015, 196 patients 
with newly diagnosed de novo DLBCL were identified 
in the clinical records in Tottori University Hospital. 
Four patients with DLBCL were not treated with che-
motherapy and thus excluded from the study; 2 were 
observed after methotrexate discontinuation, 1 received 
whole brain irradiation for palliative care and 1 under-
went splenectomy only. Ten patients with missing values 
were also excluded. Baseline clinical characteristics of 
182 patients were shown in Table 1. The median age of 
the patients was 71 years (range 18 to 91); 41 patients 
were 80 years old or more. Reduced performance status 
(> 1) was found in 43% and advanced disease (III and 
IV) was in 54%. Most patients (152 of 182, 85%) re-
ceived R-CHOP immunochemotherapy.10 However, only 
63 patients received full dose, 58 of whom completed 
6 cycles. Dose was reduced in 91 (50%) of 182 patients 
(Table 2), 74 of whom completed treatment. For patients 
with diabetes mellitus, the dose of prednisolone was 
frequently reduced. The remaining 28 patients receive 
other chemotherapies. Three patients underwent front-
line stem-cell transplantation (2 autologous and 1 allo-
geneic transplants). Five patients received consolidative 
radiation therapy to a site of bulky or residual disease. 
A variety of salvage regimens were used for refractory/
relapsed patients. The most frequent regimen used as a 
second-line treatment for fit patients was R-ICE (ritux-
imab, ifosfamide, carboplatin and etoposide) regimen 
followed by high-dose chemotherapy and autologous 
stem-cell transplantation.11
Outcome of all patients
The median follow-up time for living patients is 3.7 
years. The median survival time of all patients was not 
reached, and 3-year OS was 72% (95% CI, 64% to 78%) 
(Fig. 1A). The median PFS was 5.8 years (95% CI, 4.5 
years to NA), and 3-year PFS was 66% (95% CI, 58% to 
73%) (Fig. 2A). 
Overall survival according to prognostic indices
Outcomes of OS according to the indices are listed in 
Table 3 and are shown in Figs. 1B to F. Patients were 
evenly distributed between risk categories in the original 
IPI, age-adjusted IPI and elderly IPI while the patient 
number was skewed to the high-intermediate-risk cate-
gory in NCCN-IPI and to the poor-risk category in re-
vised IPI. The indices with 4 categories were predictive 
in this cohort and significantly discriminate risk groups 
(P < 0.001, log-rank test) with 3-year OS of low-risk, 
low-intermediate-risk, high-intermediate-risk, high-risk 
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Table 1. Baseline clinical characteristics of patients
Characteristics N %
Age*, y
≤ 40 9 5
> 40 to ≤ 60 34 19
> 60 to ≤ 75 75 41
> 75 64 35
Male gender 106 58
ECOG PS > 1 78 43
Ann Arbor stage (III or IV) 99 54
LDH, normalized
≤ 1 67 37
> 1 to ≤ 3 90 49
> 3 25 14
More than 1 extranodal site involvement 127 70
Bone marrow involvement 8 4
Liver/Gastrointestinal tract involvement 58 32
Lung involvement 3 2
CNS involvement 10 5
*Median, 71 years; range, 18 to 91. CNS, central nervous system; 
ECOG PS, Eastern Cooperative Oncology Group performance 
status; LDH, lactate dehydrogenase; y, years.
Table 2. Treatment
Treatment N %
R-containing regimen 175 96
R-CHOP, full dose 63 35
R-CHOP, reduced dose 91 50
R-COP 5 3
R only 4 2
R-MPV 3 2
DA-EPOCH-R 2 1
Other regimens* 7 4
Non-R regimen 7 4
CHOP 2 1
Other regimens* 5 3
*Various treatments including ad libitum administration of a cou-
ple of drugs. CHOP, cyclophosphamide, doxorubicin, vincristine 
and prednisolone; COP, cyclophosphamide, vincristine and pred-
nisolone; DA-EPOCH, dose-adjusted etoposide, prednisolone, 
vincristine, cyclophosphamide and doxorubicin; MPV, methotrex-
ate, procarbazine and vincristine; R, rituximab.
groups ranging from 92% to 100%, 77% to 84%, 67% to 
72% and 46% to 51%, respectively although separation 
between low-intermediate-risk and high-intermedi-
ate-risk groups was poor. Revised IPI also significantly 
discriminates risk groups (P < 0.001, log-rank test).
Progression-free survival according to prognostic 
indices
Outcomes of PFS according to the indices are listed 
in Table 3 and are shown in Figs. 2B to F. All indices 
significantly discriminate risk categories (P < 0.001, 
log-rank test except revised IPI for which P = 0.002) 
although poor separations between risk groups were fre-
quently found. 
Comparison of prognostic indices
To compare the predictive power of prognostic indices, 
we used AIC, CPE and AUC. AIC, CPE and integrated 
AUC are listed in Table 4 and AUCs of these indices are 
shown in Fig. 3. No statistical difference of performance 
was found among these indices. However, the best scores 
of model fit/discrimination measures were beaten out by 
age-adjusted IPI. In addition, AUC of age-adjusted IPI is 
better than those of other indices over time.
Significance of prognostic factors
To see the significance of prognostic factors used in 
these indices, univariate and multivariate analysis for 
OS and PFS was performed with the current cohort. P 
values are shown in Table 5 and age is not a significant 
factor regardless of cut-off point. Only number of ex-
tranodal sites and performance status remains signifi-
cant in multivariate analysis.
DISCUSSION
The outcome of all the patients is comparable to that of 
the first study reporting the superiority of R-CHOP over 
CHOP chemotherapy in patients aged 60 to 80 years; 
2-year OS was 70% (95% CI, 63 to 77) for the R-CHOP 
group in the report10 vs. 78% (95% CI, 69 to 85) for the 
patients of the same age group in the current cohort. 
Even for 64 patients older than 75 years, 2-year OS was 
73% (95% CI, 59 to 82). Rituximab was administered 
in 96% of patients in this cohort while a variety of reg-
imens were used, suggesting a survival benefit of ritux-
imab.
 The NCCN-IPI was developed to improve risk 
stratification by putting weights on age and lactate de-
hydrogenase and by restricting extranodal diseases, and 
successfully identified a high-risk group with 5-year OS 
of 33%. Nakaya et al. evaluated NCCN-IPI using 284 
Japanese patients and found no statistically significant 
discriminant power in their cohort.12 On the contrary, 
Yamada et al. reported a significant discriminant power 
of NCCN-IPI using a Japanese cohort of a similar sam-
ple size.13 In this study, NCCN-IPI was a predictable 
model. And, the outcome of a high-risk group was more 
favorable than that of the original report although a sub-
stantial number of patients were treated with reduced 
doses of R-CHOP regimen. It may be reflected by the 
fact that extranodal disease and age were not significant 
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Fig. 1. Overall survival (OS). (A) OS of all patients (solid line) with 95% confi dence interval (dotted line). (B–F) OS according to the 
original international prognostic index (IPI) (B), age-adjusted IPI (C), National Comprehensive Cancer Network (NCCN)-IPI (D), elderly 
IPI (E) and revised IPI (F). L, low-risk (black); L-I, low-intermediate risk (red); H-I, high-intermediate risk (green); H, high risk (blue); 
very good, very good risk (black); good, good risk (red); poor, poor risk (green).
Y. Hosoda et al., P. 26 
Figure 1. 
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Fig. 2. Progression-free survival (PFS). (A) PFS of all patients (solid line) with 95% confi dence interval (dotted line). (B–F) PFS accord-
ing to the original international prognostic index (IPI) (B), age-adjusted IPI (C), National Comprehensive Cancer Network (NCCN)-IPI (D), 
elderly IPI (E) and revised IPI (F). L, low-risk (black); L-I, low-intermediate risk (red); H-I, high-intermediate risk (green); H, high risk 
(blue); very good, very good risk (black); good, good risk (red); poor, poor risk (green).
Y. Hosoda et al., P. 27 
Figure 2. 
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Table 3. Distribution and outcomes of patients according to prognostic indices
OS PFS
Estimated Estimated
Index, Patients 3-year Estimated Wald 3-year Estimated Wald
Risk category Factors N (%) (95% CI) HR (95% CI) P value (95% CI) HR (95% CI) P value
IPI
Low 0, 1 44 (24) 95 (82, 99) 0.52 (0.36, 0.74) < 0.001 95 (81, 99) 0.57 (0.43, 0.75) < 0.001
Low intermediate 2 38 (21) 77 (60, 88) 0.70 (0.49, 1.00) 0.048 79 (61, 90) 0.74 (0.54, 0.99) 0.044
High intermediate 3 42 (23) 70 (52, 83) 0.54 (0.27, 1.08) 0.080 73 (55, 84) 0.63 (035, 1.13) 0.120
High 4, 5 58 (32) 51 (36, 64) 1 58 (42, 71) 1
Age-adjusted IPI
Low 0 39 (21) 95 (80, 99) 0.50 (0.35, 0.71) < 0.001 94 (79, 99) 0.58 (0.44, 0.75) < 0.001
Low intermediate 1 45 (25) 80 (64, 90) 0.58 (0.41, 0.83) 0.003 85 (69, 93) 0.56 (0.41, 0.77) < 0.001
High intermediate 2 47 (26) 71 (54, 83) 0.40 (0.20, 0.80) 0.009 73 (57, 84) 0.50 (0.28, 0.88) 0.017
High 3 51 (28) 46 (31, 61) 1 51 (34, 66) 1
NCCN-IPI
Low 0, 1 16 (9) 100 0.40 (0.20, 0.79) 0.009 92 (57, 99) 0.54 (0.36, 0.81) 0.003
Low intermediate 2, 3 48 (26) 84 (69, 92) 0.54 (0.37, 0.79) 0.001 86 (72, 94) 0.54 (0.39, 0.76) < 0.001
High intermediate 4, 5 76 (42) 72 (59, 81) 0.45 (0.25, 0.83) 0.010 78 (66, 86) 0.50 (0.29, 0.85) 0.010
High 6–8 42 (23) 46 (29, 62) 1 48 (29, 65) 1
Elderly IPI
Low 0, 1 53 (29) 92 (80, 97) 0.54 (0.40, 0.74) < 0.001 94 (81, 98) 0.60 (0.48, 0.76) < 0.001
Low intermediate 2 37 (20) 77 (59, 88) 0.70 (0.48, 0.99) 0.044 73 (55, 85) 0.72 (0.53, 0.98) 0.037
High intermediate 3 43 (24) 67 (49, 80) 0.55 (0.28, 1.09) 0.086 75 (57, 86) 0.55 (0.30, 1.00) 0.051
High 4, 5 49 (27) 49 (33, 63) 1 55 (37, 70) 1
Revised IPI
Very good 0 16 (9) 94 (63, 99) 0.35 (0.13, 0.94) 0.037 92 (57, 99) 0.48 (0.27, 0.87) 0.015
Good 1, 2 66 (36) 85 (73, 92) 0.45 (0.24, 0.83) 0.010 86 (75, 93) 0.45 (0.27, 0.76) 0.003
Poor 3–5 100 (55) 59 (48, 69) 1 64 (53, 74) 1
Hazard ratios in Cox models with the high-risk or poor-risk category as the reference group are shown. All indices significantly discrimi-
nate risk groups (P < 0.001, log-rank test except PFS by revised IPI for which P = 0.002).
CI, confidence interval; HR, hazard ratio; IPI, international prognostic index; NCCN, National Comprehensive Cancer Network; OS, 
overall survival; PFS, progression-free survival. 
predictive factors in the current cohort probably because 
of a small sample size and a short follow-up period (Table 
5). However, NCCN-IPI was considered less predictable 
in older population.13–15 Even elderly IPI, which was 
made for older population, had no improvement found in 
this cohort.
 Age-adjusted IPI, in which age is excluded from ex-
planatory factors, was initially developed as a simplified 
model of the original IPI for patients aged 60 years or 
younger. Based on AIC, CPE and AUC, age-adjusted IPI 
was found to be the best model in this cohort, the medi-
an age of which was older than 70 years. Again, it may 
be reflected by the fact that age was not significant pre-
dictive factor. The starting dose of cyclophosphamide, 
doxorubicin and vincristine in R-CHOP for patients 
older than 80 years of age was 80% of the protocol in 
our hospital and subsequent dose was adjusted if neces-
sary. The dose is relatively higher than that proposed for 
elderly patients,16, 17 which might improve the outcome of 
the elderly. 
 Modification of NCCN-IPI was attempted to im-
prove the model’s discrimination although validation 
was not performed yet.13, 15, 18 A better IPI is desired for 
ageing Japanese patients with DLBCL to discriminate 
the subgroup of patients with poor prognosis. The me-
dian follow-up period of 3.7 years was not enough to 
estimate a 5-year OS in the current cohort and 5-year 
OS rates of a high-risk groups defined by NCCN-IPI 
and by age-adjusted IPI was 46% (95% CI, 29% to 62%) 
and 42% (95% CI, 25% to 57%), respectively. Although 
longer follow-up is necessary, age-adjusted IPI is still 
usable for real-world practice in the Yonago area. 
Acknowledgments: The authors would like to thank Ms. Chiharu 
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Fig. 3. Time weighted area under the receiver operator characteristics curves (AUC). (A, B) AUC for overall survival (A) and progres-
sion-free survival (B) according to the original international prognostic index (IPI) (red), age-adjusted IPI (blue), National Comprehensive 
Cancer Network (NCCN)-IPI (green), elderly IPI (black) and revised IPI (purple). 
Y. Hosoda et al., P. 28 
Figure 3.  
A      B 
 
Table 4. Performance of prognostic indices
AIC CPE (SE) iAUC
Index OS PFS OS PFS OS PFS
IPI 493 675 0.658 (0.032) 0.645 (0.028) 0.663 0.653
Age-adjusted IPI 489 671 0.673 (0.031) 0.657 (0.027) 0.677 0.661
NCCN-IPI 493 676 0.654 (0.031) 0.638 (0.028) 0.660 0.644
Elderly IPI 493 676 0.658 (0.031) 0.640 (0.027) 0.663 0.648
Revised IPI 497 680 0.633 (0.032) 0.618 (0.028) 0.632 0.626
Low values of AIC indicate better fi t and high values of CPE and iAUC indicate better discrimination and concordance, respectively. 
AIC, Akaike’s information criteria; CPE, concordance probability estimate; iAUC, integrated area under the receiver operator curve over 
time; IPI, international prognostic index; NCCN, National Comprehensive Cancer Network; OS, overall survival; PFS, progression-free 
survival.
Table 5. Univariate and multivariate analysis for prognostic factors
OS PFS
Factor Univariate Multivariate Univariate Multivariate 
Age (years)
≤ vs. > 60 0.172 0.168
< vs. ≥ 70 0.312 0.659
< 40 vs. 41–60 vs. 61–75 vs. > 75 0.098 0.109
LDH, normalized
≤ vs. > 1 0.008 0.005
≤ 1 vs. > 1 to ≤ 3 vs. > 3 < 0.001 0.002
ECOG PS ≤ vs. > 1 < 0.001 < 0.001 < 0.001 < 0.001
Ann Arbor stage I or II vs. III or IV 0.003 < 0.001
Number of extranodal sites ≤ vs. > 1 0.001 0.010 < 0.001 0.003
Extranodal disease* vs. none 0.447 0.513
P values are shown. *Lymphomatous involvement of the bone marrow, liver/gastrointestinal tract, lung and/or central nervous system. 
ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; OS, overall survival; PFS, progres-
sion-free survival.
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